Imatinib-induced dental hyperpigmentation in childhood chronic myeloid leukemia [3]

Journal of Pediatric Hematology/Oncology

Volumn 29, Issue 3, 2007, Pages 208-209

  Singh, Navdeep ^a   Bakhshi, Sameer ^a  

^a INSTITUTE ROTARY CANCER HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB;

ADOLESCENT; ARTHRALGIA; BONE MARROW SUPPRESSION; CANCER REGRESSION; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; DIARRHEA; DRUG TOLERABILITY; EDEMA; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERPIGMENTATION; HYPOPIGMENTATION; LETTER; MUSCLE CRAMP; MYALGIA; NAUSEA; PRIORITY JOURNAL; TOOTH COLOR;

ADOLESCENT; FEMALE; GINGIVAL DISEASES; HUMANS; HYPERPIGMENTATION; LEUKEMIA, MYELOID, CHRONIC; PIPERAZINES; PYRIMIDINES; TOOTH DISEASES; TREATMENT OUTCOME;

EID: 34247646605     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e318033a76c     Document Type: Letter

References (5)

1. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of specific inhibitor of BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037.
2. Deininger MW, O'Brien SG, Ford JM, et al. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol. 2003;21:1637-1647.
3. Heinrich MC, Griffith DJ, Drucker BJ, et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571. Blood. 2000;96:925-932.
4. Okuda K, Weisberg E, Gilliland DG, et al. C-KIT tyrosine kinase activity is inhibited by ST 1571. Blood. 2001;97:2440-2448.
5. Laino G, Carinci F, Graziano A, et al. In vitro bone production using stem cells derived from human dental pulp. J Craniofac Surg. 2006;17:511-515.